Why Bother With Round Robins on Blood Tests? Q&A with Kaj Blennow
What’s with all those head-to-head comparison studies of academic and commercial biomarker tests? Could we not just pick one that works, and be done?
ALL NEWS
291 RESULTS
Sort By:
- Most Recent
- Most Commented
Nixing Complement Protein Protects Neurons in Tauopathy Model
In a tauopathy model, knocking out C3 spared synapses and neurons. In an amyloidosis model, deleting C3 preserved dendritic spines, but exacerbated plaque growth.
Healthy Lifestyle Hedges Dementia Risk, but Not if Genetic Risk Runs High
Older people who lived healthy lifestyles had a third lower risk of dementia than their unhealthy peers, but only if their genetic risk for the disease was low.
Raw Deal: Lose Ataxin, Gain BACE
Loss of ataxin-1 intensifies BACE1 expression, Alzheimer’s pathogenesis. Is that how ataxin GWAS variants increase AD risk?
Technology Brings Dementia Detection to the Home
Smartphones and gamified apps move cognitive testing from the lab into the real world. But keeping people engaged remains a problem. Is passive monitoring the answer?
Smart Homes Open Doors to Insights into Aging, Dementia
Passive monitoring of old people in their everyday lives is starting to generate new indicators for cognitive impairment.
Alzheimer's Association International Conference 2019
New PET Staging Scheme for Amyloid? Physical Activity May Shield the Brain from the Onslaught of Aβ Crenezumab Update: Baseline Data from Colombian Prevention Trial Colombian Cohort Delivers Data on Blood NfL Rare Luck: Two Copies of ApoE2 Shield Against ...
Results of Ladostigil Trial Published
The Phase 2 study missed its primary endpoint. While fewer developed dementia in the treatment group, the effect was not statistically significant. People on drug had less brain atrophy than those on placebo.
Phase 3 Trial Suggests Pimavanserin Assuages Psychosis in Dementia
The study halted early when the primary endpoint was met, but an unusual trial design and lack of detailed data leave questions unanswered.
Could Greasing the Wheels of Lipid Processing Treat Alzheimer’s?
Speakers at AD/PD 2019 reported that AD risk factors mess up lipid metabolism in glial cells. In cellular models, speeding the clearance of fats lessened pathology.
A Proteomics Dive into Cause of Frontotemporal Dementia
Proteomics and protein-protein interaction research may yield clues to etiology, tracking, and treatment of granulin-related and other forms of FTD/ALS.
Move Over Aβ, CSF P-Tau Tells Us There’s Plaque in the Brain
At AAIC, researchers touted phospho-tau species, especially p217 and p181. They tick up in CSF as an early response to amyloid accumulation.
Move Over CSF, P-Tau in Blood Also Tells Us There’s Plaque in the Brain
At this year’s AAIC, no sooner had scientists reported that phospho-tau in the CSF might reflect early responses to amyloid, than they reported parallel data for phospho-tau in blood.
Synaptic Proteins in CSF: New Markers of Cognitive Decline?
Protein levels track with cognitive function and can distinguish Alzheimer’s patients from controls.
Geneticists Seek Out Rare Contributors to Alzheimer’s
New genes linked to early and late-onset AD offer up mechanistic insight, potential targets for treatment.
Current Filters
- Date Range : Sep 2018 to Sep 2019 x